This is supported by our finding that patients whose tumours express low levels of HUWE1 expression respond better to adjuvant chemotherapy treatment than those with high levels of HUWE1. Due to the relatively high prevalence of HUWE1 mutations in a number of cancer types, this may indicate an important therapeutic window for their treatment. Here, HUWE1 is linked to neoplasm.